Advertisement
ADVANCED SEARCH

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bourgault, C. Articles by Suissa, S. Search for Related Content PubMed PubMed Citation Articles by Bourgault, C. Articles by Suissa, S. Related Collections Health Economics - see also Medicare Rationing Other drug use Other medicare

Reference-based pricing of prescription drugs

exploring the equivalence of angiotensin-converting-enzyme inhibitors

From (Bourgault, Suissa) the Department of Epidemiology and Biostatistics, McGill University, Montreal, Que.; (Bourgault, Elstein, Suissa) the Pharmacoepidemiology Research Unit, Division of Clinical Epidemiology, Royal Victoria Hospital, Montreal, Que.; and (Lorier) the Centre de recherche de l'Hotel-Dieu de Montreal, Universite de Montreal, Montreal, Que.

Abstract

Background: Reference-based pricing is a cost-containment policy applied to prescription drugs that are in the same class and deemed to be therapeutically equivalent. Recent reference-based pricing measures have targeted several drug classes, including angiotensin-converting-enzyme (ACE) inhibitors. The objective of this study was to assess whether patients treated for hypertension with various ACE inhibitors differed in their utilization of health care services and hence, whether the various ACE inhibitors should be considered therapeutically equivalent.

Methods: A retrospective cohort was formed from 4709 Saskatchewan residents aged 40-79 years who initiated treatment for hypertension with 1 of the 3 most frequently prescribed ACE inhibitors (captopril, enalapril or lisinopril) between Jan. 1, 1991, and Dec. 31, 1993. Information obtained from universal insurance databases included prescription drug use, the number of visits to a general practitioner (GP) or specialist and the number of hospital admissions during the year before treatment was initiated and during a follow-up period of up to 4 years. Rates were statistically adjusted for potential confounding variables and compared across treatment groups.

Results: Of the 4709 patients, 529 were prescribed captopril initially, 2939 enalapril and 1241 lisinopril. After treatment was initiated patients prescribed captopril were dispensed more medications on average, with an overall rate of 18.6 prescriptions per patient per year (v. 16.4 and 14.7 for enalapril and lisinopril users respectively); they were admitted to hospital more often, and they made more visits to GPs and specialists. The adjusted rate ratio of the number of visits to a GP for patients receiving enalapril, relative to captopril, was 0.84 (95% confidence interval [CI] 0.80-0.88), and for those receiving lisinopril it was 0.79 (95% CI 0.74-0.83). The adjusted rate ratios for the number of visits to a specialist were similar but lower, and for the number of hospital admissions they were 0.82 for patients prescribed enalapril initially (95% CI 0.73-0.93) and 0.65 (95% CI 0.56-0.75) for those prescribed lisinopril.

Interpretation: Patients with hypertension who are initially prescribed captopril used health care services more than those initially prescribed enalapril or lisinopril. This suggests that ACE inhibitors may not be therapeutically equivalent.

This article has been cited by other articles:

				S. Schneeweiss, M. Maclure, B. Carleton, R. J Glynn, and J. Avorn Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations BMJ, March 6, 2004; 328(7439): 560. [Abstract] [Full Text] [PDF]

				S. Schneeweiss, A. M. Walker, R. J. Glynn, M. Maclure, C. Dormuth, and S. B. Soumerai Outcomes of Reference Pricing for Angiotensin-Converting-Enzyme Inhibitors N. Engl. J. Med., March 14, 2002; 346(11): 822 - 829. [Abstract] [Full Text] [PDF]

				S. Schneeweiss, S. B. Soumerai, R. J. Glynn, M. Maclure, C. Dormuth, and A. M. Walker Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization Can. Med. Assoc. J., March 1, 2002; 166(6): 737 - 745. [Abstract] [Full Text] [PDF]

				A. Anis Why is calling an ACE an ACE so controversial? Evaluating reference-based pricing in British Columbia Can. Med. Assoc. J., March 1, 2002; 166(6): 763 - 764. [Full Text] [PDF]

				P. V. Grootendorst, L. R. Dolovich, B. J. O'Brien, A. M. Holbrook, and A. R. Levy Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs Can. Med. Assoc. J., October 1, 2001; 165(8): 1011 - 1019. [Abstract] [Full Text] [PDF]

				D. Menon Pharmaceutical Cost Control In Canada: Does It Work? Health Aff., May 1, 2001; 20(3): 92 - 103. [Abstract] [Full Text] [PDF]

				A. H. Anis Pharmaceutical policies in Canada: another example of federal-provincial discord Can. Med. Assoc. J., February 1, 2000; 162(4): 523 - 526. [Abstract] [Full Text] [PDF]

				M. McGregor Reference-based pricing Can. Med. Assoc. J., January 1, 2000; 162(1): 14 - 14. [Full Text] [PDF]

				B. Nakagawa and R. Hudson Reference-based pricing Can. Med. Assoc. J., January 1, 2000; 162(1): 12 - 12. [Full Text] [PDF]

				P. Grootendorst and A. Holbrook Evaluating the impact of reference-based pricing Can. Med. Assoc. J., August 1, 1999; 161(3): 273 - 274. [Full Text] [PDF]

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-1999, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.